Form 4: Catalyst Pharmaceuticals Director Charles B. O'Keeffe Acquires Shares and Options

Director Charles B. O'Keeffe of Catalyst Pharmaceuticals acquired shares and options through the vesting of restricted stock units and the exercise of options.

Summary

• Charles B. O'Keeffe, a director at Catalyst Pharmaceuticals, acquired 1,413 shares of common stock on December 9, 2024, through the vesting of restricted stock units.
• He also acquired 40,000 shares of common stock on December 10, 2024, by exercising options at a price of $4.01 per share.
• Following these transactions, O'Keeffe directly owns 727,137 shares of common stock.
• Additionally, he holds 253,607 restricted stock units and 213,607 options to purchase common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the director's acquisition of shares and exercise of options suggests confidence in the company's future. However, it is a routine filing and not a major event.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.
• The exercise of options at $4.01 per share indicates that the director believes the stock is worth at least that price.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the pharmaceutical industry. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, including those in the pharmaceutical sector.
• The vesting schedules for restricted stock units and options are typical for executive compensation packages in the industry.
• The transaction details are consistent with what is expected for insider trading disclosures.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates

Keywords

Catalyst Pharmaceuticals, insider trading, Form 4, stock options, restricted stock units, director, share acquisition